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Mammalian noncoding microRNAs (miRNAs) are
a class of gene regulators that have been linked to
immune system function. Here, we have investigated
the role of miR-155 during an autoimmune inflamma-
tory disease. Consistent with a positive role for miR-
155 in mediating inflammatory responses, Mir155/
mice were highly resistant to experimental autoim-
mune encephalomyelitis (EAE). miR-155 functions in
thehematopoieticcompartment topromote thedevel-
opment of inflammatory T cells including the T helper
17 (Th17) cell and Th1 cell subsets. Furthermore, the
major contribution of miR-155 to EAE was CD4+
T cell intrinsic, whereas miR-155 was also required
for optimum dendritic cell production of cytokines
that promoted Th17 cell formation. Our study shows
that one aspect of miR-155 function is the promotion
of T cell-dependent tissue inflammation, suggesting
that miR-155 might be a promising therapeutic target
for the treatment of autoimmune disorders.
INTRODUCTION
The mammalian inflammatory response has evolved to control
infection by microbial pathogens before the onset of sepsis
and death, while also playing important roles in tissue repair
(Medzhitov, 2008). Despite its utility, when the inflammatory
response is activated inappropriately, it may be directed against
specific self-tissue antigens and cause serious disease. The
outcome can be debilitating to important organ systems and
is the underlying cause of widespread human autoimmune
disorders.
Recent work has revealed that IL-17-producing inflammatory
CD4+ T cells, or T helper 17 (Th17) cells, are critical mediators of
chronic, autoimmune inflammation (Bettelli et al., 2006; Ivanov
et al., 2006). Th17 cell development is driven by cytokines
produced primarily by cells of the innate immune system,
including transforming growth factor-b (TGF-b), interleukin-6
(IL-6), IL-23, and IL-1 (Bettelli et al., 2006; Langrish et al.,
2005; Veldhoen et al., 2006). The impact of Th17 cells was firstmade evident in mice, where overexpression of IL-17 led
to increased granulopoiesis in vivo (Schwarzenberger et al.,
1998). Subsequent studies demonstrated that inhibition of
IL-17 in mice can ameliorate several autoimmune disorders
including experimental autoimmune encephalomyelitis (EAE),
collagen-induced arthritis (CIA), and inflammatory bowel dis-
ease (IBD) (Ivanov et al., 2006; Komiyama et al., 2006; Murphy
et al., 2003).
Micro-RNAs (miRNAs) are a class of noncoding RNAs that
modulate gene expression at the posttranscriptional level and
are involved in regulating several aspects of inflammation
(O’Connell et al., 2010; Xiao and Rajewsky, 2009). Specific
miRNAs, such asmiR-146a,miR-155, andmiR-132, were initially
shown to be upregulated during the macrophage inflammatory
response (O’Connell et al., 2007; Taganov et al., 2006). The func-
tional impact of certain miRNAs on inflammation has been
demonstrated in vivo. Mice deficient in miR-223, a miRNA that
is enriched in myeloid cells, display elevated granulocyte
numbers and increased immunity against fungi (Johnnidis
et al., 2008). Other studies have found important roles for
miRNAs in lymphocytes. For instance, enforced expression of
the miR-17-92 cluster in T cells or specific deletion of Dicer in
T regulatory (Treg) cells both trigger lethal autoimmune condi-
tions (Chong et al., 2008; Liston et al., 2008; Xiao et al., 2008;
Zhou et al., 2008).
miR-155 was among the first miRNAs linked to inflammation
by virtue of its potent upregulation in multiple immune cell line-
ages by Toll-like receptor (TLR) ligands, inflammatory cyto-
kines, and specific antigens (Haasch et al., 2002; O’Connell
et al., 2007; Taganov et al., 2006; Thai et al., 2007). A wide
variety of immunologically relevant targets of miR-155 have
been reported, implying distinct roles in mammalian immunity.
Among these roles, miR-155 has been shown to be important
for immunoglobulin (Ig) class switching to IgG in B cells via tar-
geted repression of activation-induced cytidine deaminase
(AID) and the transcription factor PU.1 (Dorsett et al., 2008;
Rodriguez et al., 2007; Thai et al., 2007; Vigorito et al., 2007).
The fitness of T regulatory cells is influenced by direct repres-
sion of suppressor of cytokine signaling 1 (SOCS1) by miR-
155 (Lu et al., 2009). In myeloid cells, overexpression of
miR-155 drives a myeloproliferative disorder through a mecha-
nism involving reduced src homology 2 domain-containing
inositol-5-phosphatase 1 (SHIP1) expression, suggesting thatImmunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 607
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(O’Connell et al., 2008, 2009). Despite these reported functions
of miR-155 in both innate and adaptive immune cells, to date
there has been little genetic evidence that endogenously ex-
pressed miR-155 actually impacts inflammatory responses
in vivo. In the present study, we investigated the role that
miR-155 might play during antigen-specific inflammatory
responses against self-tissues.RESULTS
Mir155–/– Mice Are Resistant to EAE Induced by Myelin
Oligodendrocyte Glycoprotein35-55
To identify a possible role for miR-155 in mediating tissue-
specific autoimmune inflammation, a mouse model of EAE was
used. Both wild-type (WT) and Mir155/ mice were immunized
with 100 mg of the myelin oligodendrocyte glycoprotein (MOG)
peptide35-55 emulsified in complete Freund’s adjuvant (CFA)
followed by administration of pertussis toxin. As anticipated,
WT mice first displayed neurologic symptoms approximately
9 days postimmunization, with peak disease severity on day 14
(average clinical score of 2.1) and 100% disease incidence
(Figures 1A and 1B). In contrast,Mir155/mice exhibited a later
onset of symptoms on day 11, with a low peak disease severity
on day 15 (average clinical score of 0.3). Unlike the WT controls,
the disease incidence inMir155/ mice was only 60% (Figures
1A and 1B). On day 25, mice were sacrificed and underwent
further evaluation including tissue histological analysis. Hema-
toxylin and eosin (H&E) brain cross-sections were scored for
disease severity (Figures 1C and 1D). As expected, WT mice
suffered from heavy perivascular congestion, parenchymal infil-
tration, and focal meningeal lymphocytosis. However, brain
tissue fromMir155/mice showed minimal histologic evidence
of inflammation consistent with the mild clinical manifestation
of EAE (Figures 1C and 1D). Furthermore, upon analyzing the
draining lymph nodes (LNs) and spleens from both groups of
mice, we found decreased overall cellularity in LNs from
Mir155/mice and compositionally fewer CD11b+myeloid cells
inMir155/ spleens (Figures 1E and 1F). Both of these observa-
tions are consistent with a reduced inflammatory condition in
Mir155/ mice.
Lethally irradiated WT C57BL/6 mice were next reconstituted
with either Mir155+/+ or Mir155/ bone marrow (BM) cells. After
4months,properengraftment and localizationof themiR-155defi-
ciency to the hematopoietic compartment was confirmed by
assayingmiR-155amounts in activated splenicBcells (Figure1G).
After inductionofEAE,micewithMir155+/+ hematopoietic cells ex-
hibited a faster and more severe disease phenotype than mice
containingMir155/hematopoieticcells (Figure1H). Inaseparate
experiment, 253 106 WT encephalitogenic splenocytes from day
12 EAE WT mice were transferred into WT or Mir155/ hosts,
which were monitored for the presence of clinical symptoms.
Both groups began to show symptoms by day 8 postadoptive
transfer and had comparable disease scores throughout the
22 day time course (Figure 1I). Furthermore, both cohorts had
a disease incidence of 100% (Figure S1 available online). Taken
together, these data demonstrate that miR-155 functions in the
hematopoietic compartment to promote EAE.608 Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc.Mir155–/– Mice Exhibit Defective Inflammatory T Cell
Development during EAE
Th17 and Th1 cells are hematopoietic cells that develop during
tissue-specific inflammatory responses and play a pivotal role
in enhancing inflammation (Littman and Rudensky, 2010). There-
fore, we examined lymph nodes (LNs) and splenocytes from WT
and Mir155/ mice for the presence of IL-17 (Th17)- or inter-
feron-g (IFN-g) (Th1)-producing CD4+ T cells during EAE. On
day 25 postimmunization with MOG35-55, Mir155
/ mice had
substantially diminished amounts of Th17 cells in both their
LNs and spleens compared to WT mice (Figures 2A and 2B).
Moderately reduced amounts of IFN-g producing Th1 CD4+ cells
were also found in the spleens but not LNs of MOG35-55 immu-
nized mice in the absence of miR-155 (Figures 2A and 2B). The
total numbers of these inflammatory T cell populations in the
spleen and LNs were also similarly reduced in Mir155/ versus
Mir155+/+ mice 25 days after immunization with MOG35-55
(Figure S2).
The in vitro recall response to the MOG35-55 peptide by WT
and Mir155/ CD4+ T cells from the spleens of EAE mice was
also assessed. Carboxyfluorescein succinimidyl ester (CFSE)-
labeled splenocytes from day 25 EAE mice were restimulated
in vitro with 20 mg/ml of MOG35-55 or cultured in medium alone
for 72 hr followed by flow cytometric analysis to determine the
extent of CD4+ proliferation as determined by dilution of CFSE.
We found that WT CD4+ T cells underwent cell divisions after
exposure to MOG35-55, whereas Mir155
/ CD4+ T cells had
a substantially reduced proliferative response to the same
peptide (Figure 2C). In parallel, 3[H] thymidine incorporation
assays via total splenocytes produced similar differences
(Figure 2D). Tissue culture supernatants from these experiments
were assayed for IL-17A and IFN-g production by ELISA
in response to MOG35-55 stimulation. MOG35-55-stimulated
Mir155/ splenocytes showed minimal production of both of
these cytokines compared to WT splenocytes, further demon-
strating a defective CD4+ T cell-driven recall response to antigen
(Figure 2E).
We next investigated whether a defect in inflammatory T cell
development could also be detected during the initial onset, or
induction phase, of EAE. Mice were harvested on day 13 postim-
munization with MOG35-55 and the LNs fromMir155
/mice had
reduced numbers of live cells compared toWT controls, whereas
the brains (CNS) andspleens from the twogroupshadsimilar total
cell numbers (Figure S3). Inflammatory T cell development in the
brains, LNs, and spleens was next assessed. Mir155/ mice
had substantial reductions in both the absolute numbers of
Th17 cells and the percentage of Th17 cells among total CD4+
T cells in their brains compared toMir155+/+ control mice (Figures
3A and 3B). IFN-g-producing Th1 cells were present at lower
absolute numbers in the brains of Mir155/ mice, whereas the
proportion of Th1 cells among total CD4+ T cells was equivalent
between Mir155/ and Mir155+/+ brains (Figure 3B). BIC (the
noncoding RNA that gives rise to miR-155) expression was de-
tected by quantitative PCR (qPCR) inMir155+/+ but notMir155/
splenocytes, and deficiencies in both IL-17A and IL-23 p19
mRNAs were also observed (Figure 3C). Intracellular staining
revealed diminished numbers of Th17 and Th1 CD4+ T cells in
Mir155/ spleens (Figure 3D). The recall response to MOG35-55
was also tested with splenocytes from day 13 EAE mice.
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Figure 1. Mir155–/– Mice Are Resistant to EAE Induced by MOG35-55
(A) EAE was induced in Mir155+/+ and Mir155/ mice by immunizing both groups with 100 mg of the MOG35-55 peptide followed by administration of pertussis
toxin. Their disease severity was scored regularly based upon clinical symptoms (n = 10). Data represent three independent experiments.
(B) Disease incidence was assessed for each group (n = 10).
(C) Representative H&E-stained brain sections from Mir155+/+ or Mir155/ mice harvested on day 25 postimmunization.
(D) Average histology score for each group (n = 4).
(E) Number of live LN cells (left) and their lineage composition was assessed by flow cytometry (right) via LNs from Mir155+/+ and Mir155/ mice 25 days after
immunization (n = 4).
(F) Number of splenocytes (left) and their lineage composition as determined by flow cytometry (right) by means of spleens from both groups 25 days after
immunization (n = 4).
(G)WTmicewere lethally irradiatedand reconstitutedwithMir155+/+orMir155/BM.4months later, expressionofmiR-155 inLPS-activatedsplenicBcellswasassessed.
(H) MOG35-55-induced EAE was induced in mice with WT orMir155
/ hematopoietic cells and disease was scored over a time course (n = 5–7).
(I) 12daysafter inductionofEAE inWTmicewithMOG35-55, splenocyteswereharvestedandcultured in20mg/mlMOG35-55 and20ng/ml IL-12p70 for 48hr.Cellswere then
washed and 253 106 cells were injected intravenously intoMir155+/+ andMir155/mice followed by administration of pertussis toxin.Miceweremonitored regularly and
disease severity was scored (n = 5). Data represent two independent experiments.
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test. See also Figure S1.
Immunity
miRNA-155 Promotes Autoimmune InflammationMir155/ splenocytes exhibited diminished proliferation during
this assay (Figure 3E). Defective production of IL-17A, IFN-g,
IL-6, and granulocyte-monocyte-colony-stimulating factor (GM-CSF) by MOG35-55-restimulated Mir155
/ encephalitogenic
splenocytes was evident (Figure 3F). Similar deficiencies in Th1
and Th17 cells were also observed in the LNs from Mir155/Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 609
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Figure 2. Mir155–/– Mice Exhibit Defective Inflammatory T Cell Development during EAE
Mir155+/+ and Mir155/ mice were harvested 25 days after immunization with MOG35-55.
(A) Intracellular staining was conducted to identify total lymph node cells (top) and CD4+ lymphocytes (bottom) producing IL-17A and/or IFN-g (n = 4). Averages
are presented graphically on the right.
(B) Splenocytes were analyzed as in (A) (n = 4).
(C)Mir155+/+ orMir155/ splenocytes harvested frommice 25 days after EAE induction were labeled with CFSE. CFSE loss by CD4+ proliferating cells from both
groups was assayed by flow cytometry after restimulation with MOG35-55 (20 mg/ml) for 72 hr (n = 4). Averages are presented graphically to the right.
(D) 3[H] thymidine incorporation was also assayed via replicate cultures from (C) (n = 4). Two naive WT mice were also included as controls.
(E) Production of IL-17A (left) and IFN-g (right) by cells from (C) was determined by ELISA (n = 4). Data represent two independent experiments.
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test. +/+ =Mir155+/+;/ =
Mir155/. See also Figure S2.
Immunity
miRNA-155 Promotes Autoimmune Inflammationmice at this same time point (Figure 3G and 3H). These data indi-
cate that the development of inflammatory T cells in Mir155/
mice is defective during the early, induction phase of EAE.610 Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc.A recent report found reduced numbers of T regulatory
cells in Mir155/ mice under steady-state conditions
(Kohlhaas et al., 2009; Lu et al., 2009). Consistent with these
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Figure 3. miR-155 Is Required for Inflammatory T Cell Development during the Induction Phase of EAE
Mir155+/+ and Mir155/ mice were harvested 13 days after immunization with MOG35-55.
(A) Mononuclear cells were purified fromMir155+/+ andMir155/ brains and intracellular staining was conducted to identify CD4+ lymphocytes producing IL-17A
and/or IFN-g (n = 5).
(B) Total numbers of Th17 and Th1 cells in the brain, in addition to the percentage of Th17 and Th1 cells among total CD4+ T cells, are shown (n = 5).
(C) WT and Mir155/ splenocytes were analyzed for expression of BIC, IL-17A, and IL-23 p19 mRNA by qPCR (n = 5).
(D) Intracellular staining was used to determine the number of Th17 and Th1 cells (n = 5).
(E and F) Splenocytes were restimulated with MOG35-55. (E) Proliferation was assayed by
3[H] thymidine incorporation (n = 5) and (F) the production of IL-17A,
IFN-g, IL-6, and GM-CSF was measured by ELISA (n = 5).
(G and H) Expression of BIC and IL-17A mRNA in the LNs was assayed by qPCR (n = 5) (G) and the number of Th17 and Th1 cells was also quantified by flow
cytometry (n = 5) (H).
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test. +/+ =Mir155+/+;/ =
Mir155/. See also Figure S3.
Immunity
miRNA-155 Promotes Autoimmune Inflammationfindings, we also observed lower Treg cell amounts in both
the LNs and spleens of Mir155/ mice compared to WT
controls during EAE (Figure S2). However, Mir155/ Tregcells are not functionally defective compared to WT Treg cells
on a per cell basis (Kohlhaas et al., 2009; Lu et al., 2009).
Thus, the reduced EAE inflammation in Mir155/ miceImmunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 611
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Figure 4. Mir155–/– Mice Have Reduced Foot Pad Inflammation during DTH
Mir155+/+ and Mir155/ mice were immunized with 100 mg of KLH in CFA and 8 days later injected with 50 mg of KLH in one footpad and PBS in the other.
(A) Increases in footpad inflammation were measured for both groups (n = 5).
(B) Total numbers of splenocytes and LN cells were assessed (n = 5).
(C) Proliferation of splenocytes and LN cells after in vitro restimulation with KLH was determined by assaying 3[H] thymidine incorporation (n = 5).
(D) Production of IL-17A, IFN-g, and IL-6 from the cells in (C) was determined by ELISA (n = 5).
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s t test. +/+ =Mir155+/+;/ =Mir155/.
Immunity
miRNA-155 Promotes Autoimmune Inflammationseems unlikely to be related to the Treg cell population in
these animals.
Also in agreement with earlier studies (Rodriguez et al., 2007;
Thai et al., 2007; Vigorito et al., 2007), we found reduced titers of
anti-MOG35-55 IgG antibodies in Mir155
/ mice during EAE
(Figure S2). It has been reported that B cells, and therefore anti-
bodies, are dispensable specifically for MOG35-55-driven EAE
(Hjelmstro¨m et al., 1998), so it is likely that the observed antibody
deficit does not account for the reduced disease severity seen in
Mir155/ mice.
Mir155–/– Mice Have Reduced Foot Pad Inflammation
during Delayed Type Hypersensitivity
Another Th17 cell-dependent model of inflammation was next
used to assess whether Mir155/ mice have a general deficit
in mediating inflammatory responses to specific antigens (Ghi-
lardi et al., 2004). WT and Mir155/ mice were immunized
with keyhole limpet hemocyanin (KLH) in complete Freund’s
adjuvant (CFA), and 8 days later challenged in one footpad612 Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc.with KLH and in the contralateral footpad with saline. After
48 hr, footpad thickness was measured to assess the delayed
type hypersensitivity (DTH) response. As expected, WT mice
had a substantial increase in footpad inflammation after KLH
administration compared to saline alone (Figure 4A). In contrast,
Mir155/ mice exhibited reduced amounts of swelling in
response to KLH as compared to WT mice (Figure 4A). Spleno-
cytes and LNs were also harvested on day 10, and Mir155/
LNs had significantly fewer total cells than WT controls, consis-
tent with a blunted inflammatory response (Figure 4B). Cells
from both organs were restimulated with KLH for 3 days.
Although LN cell and splenocyte proliferative differences were
not observed in response to stimulation with KLH (Figure 4C),
substantial reductions in IL-17A, IFN-g, and IL-6 production
were seen in Mir155/ versus WT splenocytes and LN cells
during recall responses (Figure 4D). These data support
a general role for miR-155 in mediating antigen- and tissue-
specific inflammation and point to a consistent defect in inflam-
matory T cell production.
A B
C D
Figure 5. miR-155 Expression by CD4+ T
Cells Is Necessary for Proper Th17 Cell
Development In Vitro
(A) CD4+ T cells were isolated from Mir155+/+
or Mir155/ spleens and cultured in the pres-
ence of plate-bound CD3 and soluble CD28 anti-
bodies, with (Th17 cell) and without (Th0 cell) IL-6
(50 ng/ml) and TGF-b (2 ng/ml). After 96 hr, expres-
sion of IL-17A and IFN-g was assayed by intracel-
lular staining followed by flow cytometry.
(B) Results from a representative experiment are
represented graphically (n = 2). Data represent
three independent experiments.
(C) Expression of miR-155 wasmeasured by qPCR
before and after activation with CD3 and CD28
antibodies (n = 3).
(D) Expression of BIC, miR-155, and IL-17A in WT
and Mir155/ CD4+ T cells was assayed by
qPCR after 96 hr of culture with CD3 and CD28
antibodies alone, or in Th17 cell skewing condi-
tions (n = 2).
Data represent two independent experiments.
Error bars represent ±SEM.
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of Inflammatory T Cells during EAE
Inflammatory T cells must be able to properly receive and coordi-
nate the signals provided by specific inflammatory cytokines that
mediate their development. Therefore, we tested whether miR-
155 expression by CD4+ T cells is involved in their ability to be
skewed toward the Th17 cell lineage in vitro. CD4+ splenic
T cells were isolated from Mir155+/+ and Mir155/ mice and
cultured in the presence of CD3 and CD28 antibodies with
and without the addition of the Th17 cell skewing factors IL-6
and TGF-b. After 4 days of culture, we found that Mir155/
CD4+ T cells were defective in their ability to produce Th17 cells
compared to WT controls as assayed by intracellular staining of
IL-17A (Figures 5A and 5B). The same cell populations and
culture conditions produced similar amounts of IFN-g+ Th1 cells
despite the miR-155 deficiency (Figures 5A and 5B). As in
previous reports (Haasch et al., 2002), we also observed upregu-
lation of miR-155 in activated CD4+ T cells (Figure 5C), and we
detected expression of BIC and miR-155 in CD4+ T cells grown
in conditions that promote Th17 cell development (Figure 5D).
Reduced expression of IL-17A mRNA was measured in
Mir155/ compared toWTCD4+ T cells under Th17 cell skewing
conditions (Figure 5D). These results reveal a T cell-intrinsic role
for miR-155 in promoting the in vitro development of Th17 cells.
To test whether miR-155 plays a T cell-intrinsic role in driving
inflammatory T cell development during EAE in mice, we adop-
tively transferred 6 3 106 purified naive Mir155+/+ or Mir155/
CD4+ T cells intoRag1/ recipients and induced EAE 24 hr later.
Mice receiving Mir155+/+ CD4+ T cells had a substantially more
severe and accelerated disease course compared to mice
receivingMir155/ CD4+ T cells (Figure 6A). Reduced percent-
ages of Th17, and to a lesser extent Th1, CD4+ T cells was
observed in the spleens and LNs from mice that receivedMir155/ CD4+ T cells compared to those engrafted with
Mir155+/+ CD4+ T cells (Figures 6B and 6C).
To examine whether miR-155 expression specifically in CD4+
T cells could restore disease severity in Mir155/ mice, we
adoptively transferred 1 3 107 naive CD45.1+CD4+ T cells into
both WT and Mir155/ recipients and induced EAE 24 hr later.
AlthoughMir155+/+ mice began to show clinical symptoms a few
days before Mir155/ mice, both groups exhibited similar
disease scores for most of the time course (Figure 6D). The
brain was harvested on day 23 postimmunization, and the
development of Th17 and Th1 cells was determined by intracel-
lular staining for IL17A and IFN-g, respectively (Figures 6E and
6F; Figure S4). Although both mouse groups had roughly equiv-
alent percentages of both Th17 and Th1 cells among the total
CD4+ T cells in the brain, these cellular subsets were comprised
predominately of the adoptively transferred CD45.1+CD4+ WT
T cells in the CNS ofMir155/mice. This bias occurred despite
roughly similar amounts of both WT andMir155/ CD4+ T cells
being present in the brains of Mir155/ EAE mice (Figures 6E
and 6F). Conversely, these same inflammatory T cell populations
were comprised largely of endogenous origin (CD45.1CD4+
Mir155+/+ T cells) in the CNS of Mir155+/+ mice (Figures 6E and
6F). These data demonstrate that miR-155 expression by CD4+
T cells is critical for the proper development of inflammatory
T cell subsets in the CNS and that this accounts for a majority
of miR-155’s contribution to EAE.
miR-155 Expression Is Necessary for Proper Secretion
of Th17 Cell-Related Inflammatory Cytokines by DCs
Because of the lag in EAE phenotype development when WT
CD4+ T cells were administered toMir155/mice, it is possible
that miR-155 also functions in non-T cell immune cell types to
promote inflammatory T cell development. For encephalitogenicImmunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 613
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Figure 6. Expression of miR-155 by CD4+ T Cells Is Required for Proper Development of Inflammatory T Cells during EAE
(A) 53 106 WT orMir155/CD4+ T cells from naive mice were injected i.v. into Rag1/ recipients, EAE was induced with MOG35-55 24 hr later, and disease was
scored over a time course (n = 5–6). Data represent two independent experiments.
(B) Mice were harvested and engraftment of CD3+CD4+ T cells was assayed by flow cytometry with splenocytes (top). Expression of IL-17A and IFN-g by CD4+
cells in the spleens and LNs was assayed by intracellular staining followed by flow cytometry. A representative plot from the LNs is shown (bottom).
(C) The averages of 5–6 mice per group are shown graphically.
(D)Mir155+/+ andMir155/mice were injected with 1 3 107 WT CD45.1+CD4+ naive T cells, and EAE was induced 24 hr later (n = 5). Disease symptoms were
scored over a time course. Data represent two independent experiments.
(E) Mice were harvested and CD4+ T cells in the brains were analyzed by flow cytometry to detect cells expressing CD45.1, IL-17A, and IFN-g.
(F) The average of five mice per group from (E).
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test. +/+ =Mir155+/+;/ =
Mir155/. See also Figure S4.
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miRNA-155 Promotes Autoimmune InflammationTh17 cells to develop, they must receive signals from relevant
inflammatory cytokines, such as IL-6 and IL-23, which are
produced by GM-CSF-derived DCs (Gutcher and Becher,
2007). Therefore, we examined the impact of miR-155 on the
gene expression profile of LPS-activated DCs, which express
high levels of miR-155 (Figures 7A and 7B). Total RNA was
collected from purified WT or Mir155/ DCs after 20 hr of LPS
treatment and subjected to a microarray analysis. Several
targets of miR-155 were expressed at higher amounts in
Mir155/ versus WT control DCs (Figure 7C). Among these,
SHIP1 and SOCS1 have been shown to be directly targeted by
miR-155 (Androulidaki et al., 2009; Lu et al., 2009; O’Connell
et al., 2009) and to function by negatively regulating cytokine
production by DCs (An et al., 2005; Shen et al., 2004). Their
elevated expression in Mir155/ DCs was confirmed via quan-
titative PCR (qPCR) and by immunoblotting (Figure 7D). Consis-
tent with the elevated expression of these negative regulators,
decreased expression of several inflammatory cytokine genes
including IL-6, IL-23 p19, and IL-12 and IL-23 p40 was observed
in Mir155/ DCs (Figure 7C). These results were confirmed by
qPCR and ELISA, which also detected a subtle decrease in
tumor necrosis factor-a (TNF-a) production (Figures 7E and
7F). To further corroborate these findings, miR-155 was overex-
pressed in GM-CSF-derived DCs via a retroviral vector
described previously (O’Connell et al., 2009), and higher
amounts of IL-6, IL-23 p19, IL-12 and IL-23 p40, and TNF-a
mRNA expression were observed after LPS treatment
(Figure 7G). We also tested whetherMir155/ DCs were defec-
tive in their ability to induce CD4+ T cell proliferation after presen-
tation of cognate antigens. Both Mir155+/+ and Mir155/ DCs
induced equivalent proliferation of 2D2 or OT2 CD4+ T cells
that recognize MOG35-55 or an ovalbumin peptide, respectively
(Figure 7H). Taken together, these experiments demonstrate
that miR-155 promotes DC expression of specific cytokines
required for inflammatory T cell development.
DISCUSSION
We have shown here that miR-155 plays an important role in
driving chronic inflammation that is inappropriately directed at
tissue-specific antigens, a destructive process that is at the heart
of human autoimmune diseases. At the cellular level, Mir155/
mice exhibit defective inflammatory T cell development during
the induction phase of autoimmunity. This appears to be largely
due to miR-155 function in CD4+ T cells, and may also involve
insufficient production of inflammatory cytokines by DCs.
Although diminished inflammatory T cell development is benefi-
cial in the context of autoimmunity, it is detrimental to mammals
after infection by certain pathogens. Thus, our observations also
suggest a protective role for miR-155 in response to infection.
miR-155 expression is dramatically increased in CD4+ T cells
upon their activation, suggesting functional importance for this
miRNA in activated T cells (Haasch et al., 2002). Our results
expand upon previous work, which demonstrated that miR-
155 can impact Th1 cell and Th2 cell lineage skewing in vitro
(Rodriguez et al., 2007; Thai et al., 2007), by finding a role for
miR-155 in Th17 cell biology both in vitro and in vivo. Recently,
inhibition of miR-326 via a miRNA ‘‘sponge’’ was shown to
reduce EAE symptoms by preventing Th17 cell differentiationalso through a T cell-intrinsic mechanism (Du et al., 2009).
Thus, multiple miRNAs appear to directly regulate inflammatory
T cell development, as suggested by early studies analyzing
Dicer-deficient T cells (Muljo et al., 2005).
Many direct targets ofmiR-155 in CD4+ T cells have been iden-
tified, some of which impact Th cell lineage decisions (Rodriguez
et al., 2007). For instance, c-Maf is targeted by miR-155 and
functions as a promoter of Th2 cell development (Rodriguez
et al., 2007), while SOCS1 is repressed by miR-155 in both
FoxP3+CD4+ Treg cells and FoxP3 CD4+ T cells and impacts
Treg cell fitness (Lu et al., 2009). In general, a complex picture of
howmiR-155 directs T cell developmental pathways is emerging
and it appears to involve many targets and pathways. This may
also be true for miR-155’s positive role in Th17 cell development.
On one hand, miR-155 might function to block the inhibitory
impact of cytokines such as IL-4 and IFN-g on the Th17 cell differ-
entiation pathway.miR-155 hasbeen shown to limit productionof
IL-4 byCD4+ T cells through repression of c-Maf (Rodriguez et al.,
2007),while IFN-gRmRNA isdirectly targetedbymiR-155 inCD4+
T cells (Banerjee et al., 2010). However, we found that WT CD4+
T cells restore EAE disease severity following their adoptive
transfer into Mir155/ mice. This argues against a major role
for elevated production of a secreted inhibitory molecule like
IL-4 being responsible for the reduced EAE observed in
Mir155/ mice because it would also inhibit the transferred WT
T cells through a paracrine mechanism.
Alternatively, it is possible that miR-155 can positively regulate
signaling pathways that promote Th17 cell formation. This could
be achieved via repression of proteins that function to negatively
regulate signaling pathways that are activated by TGF-b, IL-6,
and IL-23. Although it is unclear whether miR-155 directly regu-
lates these pathways in CD4+ T cells, recent studies found that
miR-155 targets Sma- and Mad-related protein 5 (Smad5) in B
cell lymphoma cells (Rai et al., 2010) and activates signal trans-
ducer and activator of transcription 3 (Stat3) in breast cancer
cells (Jiang et al., 2010), factors involved in TGF-b and IL-6
signaling, respectively. Moving forward, the identity and relative
importance of each target of miR-155 during the development of
different T cell lineages, including Th17 cells, should continue to
be investigated, and may reveal a differential importance for
unique targets of miR-155 depending on the T cell subset.
Interestingly, a previous study found that Mir155/
FoxP3CD4+ T cells were at a competitive disadvantage in the
presence of WT FoxP3CD4+ T cells under steady-state condi-
tions (Lu et al., 2009). During our EAE phenotype ‘‘rescue’’ exper-
iments, Mir155/ CD4+ T cells also showed reduced fitness
compared to the adoptively transferred WT CD4+ T cells. Thus,
the role of miR-155 in conferring CD4+ T cell fitness extends to
inflammatory settings where miR-155 is also required for proper
inflammatory T cell differentiation. These reductions in fitness
and differentiation by effector T cells may explain whyMir155/
mice do not succumb to spontaneous systemic autoimmunity
or suffer from heightened EAE symptoms as a consequence of
their reduced Treg cell numbers (Lu et al., 2009).
Similar to Mir155/ mice, GM-CSF-deficient mice are also
resistant to EAE (McQualter et al., 2001) and GM-CSF-derived
DCs have recently been linked to Th17 cell development during
autoimmunity by functioning as an important source of the Th17
cytokines IL-6 and IL-23 (Sonderegger et al., 2008). Our presentImmunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 615
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Figure 7. miR-155 Expression by LPS-Activated, GM-CSF-Derived Myeloid Dendritic Cells Is Necessary for Proper Production of Th17
Cell-Relevant Inflammatory Cytokines
(A) CD11c+ DCs were derived with GM-CSF at 20 ng/ml.
(B) Expression of BIC (top) and mature miR-155 (bottom) before and after 20 hr of LPS stimulation (100 ng/ml) was assayed via qPCR.
(C) Total RNA was next used for a microarray analysis to determine mRNA expression differences between Mir155+/+ and Mir155/ LPS-treated DCs. Several
selected targets of miR-155 were expressed in higher amounts inMir155/DCs, while a subset of selected proinflammatory cytokines were expressed at lower
amounts. Red, higher expression; green, lower expression in the Mir155/ versus Mir155+/+ DCs.
(D) Expression of SHIP1 and SOCS1 mRNAs was assessed by qPCR and by immunoblotting (n = 3).
(E) qPCR was also used to assay expression of IL-23 p19, IL-6, IL-12 and IL-23 p40, and TNF-amRNA amounts (n = 3). Data represent two independent exper-
iments.
(F) Concentrations of the cytokines from (E) in the culture supernatants were determined by ELISAs (n = 3). Data represent two independent experiments.
(G) GM-CSF-derived DCs overexpressingmiR-155, amiR-155 ‘‘seed’’ mutant, or a control vector were stimulated with LPS for 20 hr and expression of IL-23 p19,
IL-6, IL-12 and IL-23 p40, and TNF-a mRNA was assayed by qPCR. Data represent two independent experiments.
(H) Proliferation of 2D2 or OT2 CD4+ T cells in response to their respective antigens presented byWT orMir155/DCs was assessed by assaying 3[H] thymidine
incorporation (n = 3). Data represent two independent experiments.
Error bars represent ±SEM and asterisk denotes statistical significance with a p value of < 0.05 according to a Student’s two-tailed t test.
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derived DCs and functions to enhance production of these cyto-
kines. Thismaycontribute to thedefects in Th17cell development
and tissue-specific inflammation observed in theMir155/mice.
Additionally, because Th17 cells are a primary source of GM-CSF
during EAE (Ponomarev et al., 2007), they are thought to reinforce
this chronic inflammatory condition by generating additional DCs.
Thus, the defective production of Th17 cells in Mir155/ mice
during EAE may also explain the reduced amounts of GM-CSF
observed during our splenocyte recall response experiments.
Together, our data suggest a role for miR-155 in regulating both
the production and function of GM-CSF-derived DCs in the
promotion of autoimmune inflammation.
Elevated expression of miR-155 has been observed in brain
lesions from multiple sclerosis (MS) patients (Junker et al.,
2009) and in synovial samples from patients with rheumatoid
arthritis (RA) (Stanczyk et al., 2008). Human trials have found
that inhibition of the IL-23-IL-17 inflammatory axis via blocking
antibodies can reduce the severity of psoriasis and rheumatoid
arthritis (Steinman, 2010). Based upon this expression profile
and our current study, miR-155 may be an effective therapeutic
target in the treatment of a range of autoimmune conditions
where Th17 cells have been shown to drive disease. However,
delivery of miRNA inhibitors to specific cell types in vivo remains
a difficult challenge.
In addition to inflammatory T cells, many autoimmune condi-
tions, including human MS, RA, and systemic lupus erythemato-
sus (SLE), also involve the actions of auto-antibodies that have
been shown to exacerbate these diseases. Beyond its role in
mediating inflammatory T cell development as identified in our
current study, previous reports have clearly shown that miR-
155 is important for production of antigen-specific IgGs (Rodri-
guez et al., 2007; Thai et al., 2007; Vigorito et al., 2007). There-
fore, modulation of miR-155 may be able to treat conditions
that depend both upon humoral and cell-mediated immune
mechanisms, making it a versatile therapeutic target.EXPERIMENTAL PROCEDURES
Mice
All experiments were approved by the Caltech Institutional Animal Care and
Use Committee (IACUC). Mir155+/+, Mir155/, Rag1/, CD45.1+, OT2, and
2D2 mice are all on a C57BL/6 genetic background. For bone marrow recon-
stitutions, mice were conditioned with 1000 Rads via a Cs137 source prior to
injection of donor BM.Mouse Models of EAE and DTH
For induction of EAE, mice were injected subcutaneously (s.c.) into the base
of the tail with a volume of 200 ml containing 100 mg/ml MOG35-55 peptide
(GenScript) emulsified in complete Freund’s adjuvant (CFA). Mice were also
injected intraperitoneally (i.p). with 200 ng of pertussis toxin on days 0 and 2,
and clinical symptoms were scored regularly according to the following
criteria: 0, no symptoms; 0.5, partially limp tail; 1, completely limp tail; 1.5,
impaired righting reflex; 2, hind limb paresis; 2.5, hind-limb paralysis; 3, fore-
limb weakness; 4, complete paralysis; 5, death. For induction of DTH
responses, keyhole limpet hemocyanin (KLH) was purchased from Calbio-
chem. Mice were immunized s.c. at the base of the tail with 100 mg KLH in
200 ml CFA. To assess DTH, all mice involved in the studies were given
50 mg KLH in 50 ml PBS intradermally into the left foot pad and 50 ml phosphate
buffered saline (PBS) alone in the right foot pad 8 days after the immunization.
2 days later, foot pad swelling was measured.Cell Culture and Reagents
DCswere derived fromWT orMir155/RBC-depleted bonemarrow via rGM-
CSF (ebioscience) at a concentration of 20 ng/ml in complete RPMI (supple-
mented with 10% FBS, 100 units/ml penicillin, 100 units/ml streptomycin,
50 mM beta-mercaptoethanol). Cells were cultured at 5% CO2 and 37
C in
a humidified incubator. DCs were stimulated with E. coli LPS (Sigma) at
a concentration of 100 ng/ml. For Th17 cell skewing, CD4+ splenocytes
were cultured in complete RPMI, plate-bound CD3 antibodies, and soluble
CD28 antibodies (2 mg/ml), IL-6 (50 ng/ml), and TGF-b (2 ng/ml) (Biolegend)
for 96 hr. Splenocytes or LN cells were also cultured in complete RPMI during
restimulation with relevant antigens. The MOG35-55 peptide was synthesized
by Genscript. KLH was obtained from Calbiochem. For CFSE experiments,
253 106 splenocytes were labeled in 5 mM CFSE for 10 min at 37C, washed,
and cultured. Cellular proliferation was also assayed by pulsing cells with 3[H]
thymidine (1 mCi/well) for the final 18 hr. For coculture assays, WT orMir155+/+
DCs were pulsed with the MOG35-55 peptide or Ovalbumin and used to acti-
vated purified 2D2 or OT2 CD4+ T cells, respectively, at a 1:10 ratio. For
some experiments, splenocytes were obtained from day 12 EAE WT mice
and culturedwith 20 mg/ml MOG35-55 and 20 ng/ml IL-12 for 2 days before cells
were washed and injected intravenously.Intracellular Staining and Flow Cytometry
To detect intracellular expression of IL-17A, IFN-g, or FoxP3 in CD4+ spleno-
cytes, LNs or brain cells (purified with Percoll) were first treated with 750 ng/ml
ionomycin and 50 ng/ml phorbol myristate acetate (PMA) (Calbiochem) in the
presence of 0.5 ml of GolgiPlug (BD Biosciences) for 4–5 hr at 37C. Cells were
subsequently surface stained with CD4+ antibodies and then permeabilized
and fixed in 100 ml of eBioscience Perm-Fix solution overnight at 4C. Cells
were washed once in perm wash buffer (eBioscience) and then stained with
0.3 mg of fluorophore-conjugated anti-IL-17A, IFN-g, or FoxP3 (eBioscience)
for 20 min at 4C. Fluorophore-conjugated monoclonal antibodies specific
to CD11b (Mac1), CD33, or B220 (eBioscience) were used to stain red blood
cell (RBC)-lysed splenocytes or LN cells. Antibodies recognizing CD11c (eBio-
science) were also used to stain in vitro derived DCs. After washing, stained
cells were assayed with a BD FACSCalibur flow cytometer and results further
processed with FlowJo software.Microarray and qPCR
Total RNA was isolated from magnetic-activated cell separation (MACS)-
sorted, LPS-activated CD11c+ myeloid DCs derived from WT or Mir155/
BM via Trizol (Invitrogen) per manufacturer’s instructions. Global mRNA
expression amounts were next assayed with the Affymetrix total mouse
genome array V 2.0 as described previously (O’Connell et al., 2008), and the
data were analyzed further with Rosetta Resolver software. Sybrgreen-based
quantitative real-time PCR (qPCR) was conducted with the 7300 Realtime PCR
system (Applied Biosystems, Foster City, CA) to assay BIC, SHIP1, SOCS1, IL-
17A, IL-6, IL-23 p19, IL-12 and IL-23 p40, TNF-a, and L32mRNA amounts with
gene-specific primers (sequences available upon request). Mature miR-155
and sno202 RNA amounts were assayed with specific Taqman probes from
Applied Biosystems. For all experiments, mRNA was normalized to L32 and
miRNA to sno202.ELISAs
To detect protein expression of GM-CSF, IL-6, IL-17A, IFN-g, IL-23 p19 and
p40, IL-12 and IL-23 p40, and TNF-a, ELISAs were performed with cytokine-
specific kits from eBioscience and carried out according to the manufacturer’s
instructions. Serum IgG antibodies against MOG35-55 were assayed by plating
serial dilutions of mouse serum on plates coated with MOG35-55 and bound
antibodies detected with biotinylated anti-mouse IgG antibodies and Strepta-
vidin horseradish peroxidase (HRP) (Southern Biotech).Immunoblotting
Cellular extract was size fractionated via sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) and immunoblotting was performed
in accordance with standard protocols. Specific antibodies were used to
detect SHIP1, SOCS1, and b-actin.Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 617
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Murine stem cell virus (MSCV)-based retroviruses expressing murine miR-155
were prepared as described previously (O’Connell et al., 2009) and used
to spin infect freshly isolated WT bone marrow. Immediately following,
cells were cultured in GM-CSF containing medium until day 7 before LPS
stimulation.
Histological Examination of Central Nervous System Tissues
Brains and spinal cords from EAE mice were dissected and fixed in formalde-
hyde for 48 hr. Tissue sections were next prepared, stained with H&E, and visu-
alized with a Nikon Eclipse 50i microscope, and photographed with a Spot
digital camera. Sections were scored by a pathologist blinded to the genotype
of the tissue or the clinical severity of disease according to the following criteria:
0, no sign of infiltrate; 1, perivascular congestion (light); 2, perivascular conges-
tion (heavy); 3, perivascular congestion (heavy) and parenchymal infiltrate; 4,
focal meningeal lymphocytosis; 5, extensive sclerosis.
Statistical Analysis
Statistical significance was determined by performing a two-tailed t test.
p values < 0.05 were considered significant.ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE23641.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.immuni.2010.09.009.
ACKNOWLEDGMENTS
R.M.O. was funded in part by the Irvington Institute Fellowship Program of the
Cancer Research Institute and by award number K99HL102228 from the
National Heart, Lung and Blood Institute. D.K. was supported by the National
Institutes of Health—Building Interdisciplinary Research Careers in Women’s
Health (BIRCWH) center at UCLA (K12 HD001400). A.A.C. was funded by
the Graduate Research Fellowship Program of the National Science Founda-
tion. D.S.R. was funded by award number 1K08CA133521 from the National
Cancer Institute. J.L.R. is a Merck Fellow of the Jane Coffin Child’s Memorial
Fund. This work was also supported by NIH grant 1R01AI079243-01. We
would like to thank A. Bradley for providing us with Mir155/ animals. D.B.
is a scientific advisor to Regulus Therapeutics, a company devoted to micro-
RNA therapeutics.
Received: April 5, 2010
Revised: July 19, 2010
Accepted: September 13, 2010
Published online: September 30, 2010
REFERENCES
An, H., Xu, H., Zhang, M., Zhou, J., Feng, T., Qian, C., Qi, R., and Cao, X.
(2005). Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1)
negatively regulates TLR4-mediated LPS response primarily through a phos-
phatase activity- and PI-3K-independent mechanism. Blood 105, 4685–4692.
Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zachar-
ioudaki, V., Margioris, A.N., Tsichlis, P.N., and Tsatsanis, C. (2009). The kinase
Akt1 controls macrophage response to lipopolysaccharide by regulating
microRNAs. Immunity 31, 220–231.
Banerjee, A., Schambach, F., DeJong, C.S., Hammond, S.M., and Reiner, S.L.
(2010). Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur. J.
Immunol. 40, 225–231.618 Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc.Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Weiner, H.L.,
and Kuchroo, V.K. (2006). Reciprocal developmental pathways for the gener-
ation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238.
Chong, M.M., Rasmussen, J.P., Rudensky, A.Y., Rundensky, A.Y., and Litt-
man, D.R. (2008). The RNAseIII enzyme Drosha is critical in T cells for prevent-
ing lethal inflammatory disease. J. Exp. Med. 205, 2005–2017.
Dorsett, Y., McBride, K.M., Jankovic, M., Gazumyan, A., Thai, T.H., Robbiani,
D.F., Di Virgilio, M., San-Martin, B.R., Heidkamp, G., Schwickert, T.A., et al.
(2008). MicroRNA-155 suppresses activation-induced cytidine deaminase-
mediated Myc-Igh translocation. Immunity 28, 630–638.
Du, C., Liu, C., Kang, J., Zhao, G., Ye, Z., Huang, S., Li, Z., Wu, Z., and Pei, G.
(2009). MicroRNA miR-326 regulates TH-17 differentiation and is associated
with the pathogenesis of multiple sclerosis. Nat. Immunol. 10, 1252–1259.
Ghilardi, N., Kljavin, N., Chen, Q., Lucas, S., Gurney, A.L., and De Sauvage,
F.J. (2004). Compromised humoral and delayed-type hypersensitivity
responses in IL-23-deficient mice. J. Immunol. 172, 2827–2833.
Gutcher, I., and Becher, B. (2007). APC-derived cytokines and T cell polariza-
tion in autoimmune inflammation. J. Clin. Invest. 117, 1119–1127.
Haasch, D., Chen, Y.W., Reilly, R.M., Chiou, X.G., Koterski, S., Smith, M.L.,
Kroeger, P., McWeeny, K., Halbert, D.N., Mollison, K.W., et al. (2002). T cell
activation induces a noncoding RNA transcript sensitive to inhibition by
immunosuppressant drugs and encoded by the proto-oncogene, BIC.
Cell. Immunol. 217, 78–86.
Hjelmstro¨m, P., Juedes, A.E., Fjell, J., and Ruddle, N.H. (1998). B-cell-deficient
mice develop experimental allergic encephalomyelitis with demyelination
after myelin oligodendrocyte glycoprotein sensitization. J. Immunol. 161,
4480–4483.
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille,
J.J., Cua, D.J., and Littman, D.R. (2006). The orphan nuclear receptor ROR-
gammat directs the differentiation program of proinflammatory IL-17+ T helper
cells. Cell 126, 1121–1133.
Jiang, S., Zhang, H.W., Lu, M.H., He, X.H., Li, Y., Gu, H., Liu, M.F., and Wang,
E.D. (2010). MicroRNA-155 functions as an OncomiR in breast cancer by
targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70,
3119–3127.
Johnnidis, J.B., Harris, M.H., Wheeler, R.T., Stehling-Sun, S., Lam, M.H.,
Kirak, O., Brummelkamp, T.R., Fleming, M.D., and Camargo, F.D. (2008).
Regulation of progenitor cell proliferation and granulocyte function by micro-
RNA-223. Nature 451, 1125–1129.
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R.,
Lassmann, H., Wekerle, H., Hohlfeld, R., and Meinl, E. (2009). MicroRNA
profiling of multiple sclerosis lesions identifies modulators of the regulatory
protein CD47. Brain 132, 3342–3352.
Kohlhaas, S., Garden, O.A., Scudamore, C., Turner, M., Okkenhaug, K., and
Vigorito, E. (2009). Cutting edge: The Foxp3 target miR-155 contributes to
the development of regulatory T cells. J. Immunol. 182, 2578–2582.
Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S.,
Sudo, K., and Iwakura, Y. (2006). IL-17 plays an important role in the develop-
ment of experimental autoimmune encephalomyelitis. J. Immunol. 177,
566–573.
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedg-
wick, J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J. (2005). IL-23 drives
a pathogenic T cell population that induces autoimmune inflammation. J. Exp.
Med. 201, 233–240.
Liston, A., Lu, L.F., O’Carroll, D., Tarakhovsky, A., and Rudensky, A.Y. (2008).
Dicer-dependent microRNA pathway safeguards regulatory T cell function.
J. Exp. Med. 205, 1993–2004.
Littman, D.R., and Rudensky, A.Y. (2010). Th17 and regulatory T cells in medi-
ating and restraining inflammation. Cell 140, 845–858.
Lu, L.F., Thai, T.H., Calado, D.P., Chaudhry, A., Kubo, M., Tanaka, K., Loeb,
G.B., Lee, H., Yoshimura, A., Rajewsky, K., and Rudensky, A.Y. (2009).
Foxp3-dependent microRNA155 confers competitive fitness to regulatory
T cells by targeting SOCS1 protein. Immunity 30, 80–91.
Immunity
miRNA-155 Promotes Autoimmune InflammationMcQualter, J.L., Darwiche, R., Ewing, C., Onuki, M., Kay, T.W., Hamilton, J.A.,
Reid, H.H., and Bernard, C.C. (2001). Granulocyte macrophage colony-stimu-
lating factor: A new putative therapeutic target in multiple sclerosis. J. Exp.
Med. 194, 873–882.
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature
454, 428–435.
Muljo, S.A., Ansel, K.M., Kanellopoulou, C., Livingston, D.M., Rao, A., and
Rajewsky, K. (2005). Aberrant T cell differentiation in the absence of Dicer.
J. Exp. Med. 202, 261–269.
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClanahan, T.,
Kastelein, R.A., Sedgwick, J.D., and Cua, D.J. (2003). Divergent pro- and anti-
inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
J. Exp. Med. 198, 1951–1957.
O’Connell, R.M., Taganov, K.D., Boldin, M.P., Cheng, G., and Baltimore, D.
(2007). MicroRNA-155 is induced during the macrophage inflammatory
response. Proc. Natl. Acad. Sci. USA 104, 1604–1609.
O’Connell, R.M., Rao, D.S., Chaudhuri, A.A., Boldin, M.P., Taganov, K.D., Nic-
oll, J., Paquette, R.L., and Baltimore, D. (2008). Sustained expression of micro-
RNA-155 in hematopoietic stem cells causes a myeloproliferative disorder.
J. Exp. Med. 205, 585–594.
O’Connell, R.M., Chaudhuri, A.A., Rao, D.S., and Baltimore, D. (2009). Inositol
phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA
106, 7113–7118.
O’Connell, R.M., Rao, D.S., Chaudhuri, A.A., and Baltimore, D. (2010). Physi-
ological and pathological roles formicroRNAs in the immune system. Nat. Rev.
Immunol. 10, 111–122.
Ponomarev, E.D., Shriver, L.P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi,
D., and Dittel, B.N. (2007). GM-CSF production by autoreactive T cells is
required for the activation of microglial cells and the onset of experimental
autoimmune encephalomyelitis. J. Immunol. 178, 39–48.
Rai, D., Kim, S.W., McKeller, M.R., Dahia, P.L., and Aguiar, R.C. (2010). Target-
ing of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphoma-
genesis. Proc. Natl. Acad. Sci. USA 107, 3111–3116.
Rodriguez, A., Vigorito, E., Clare, S., Warren, M.V., Couttet, P., Soond, D.R.,
van Dongen, S., Grocock, R.J., Das, P.P., Miska, E.A., et al. (2007). Require-
ment of bic/microRNA-155 for normal immune function. Science 316,
608–611.
Schwarzenberger, P., La Russa, V., Miller, A., Ye, P., Huang, W., Zieske, A.,
Nelson, S., Bagby, G.J., Stoltz, D., Mynatt, R.L., et al. (1998). IL-17 stimulatesgranulopoiesis in mice: Use of an alternate, novel gene therapy-derived
method for in vivo evaluation of cytokines. J. Immunol. 161, 6383–6389.
Shen, L., Evel-Kabler, K., Strube, R., and Chen, S.Y. (2004). Silencing of
SOCS1 enhances antigen presentation by dendritic cells and antigen-specific
anti-tumor immunity. Nat. Biotechnol. 22, 1546–1553.
Sonderegger, I., Iezzi, G., Maier, R., Schmitz, N., Kurrer, M., and Kopf, M.
(2008). GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17
cell development and survival. J. Exp. Med. 205, 2281–2294.
Stanczyk, J., Pedrioli, D.M., Brentano, F., Sanchez-Pernaute, O., Kolling, C.,
Gay, R.E., Detmar, M., Gay, S., and Kyburz, D. (2008). Altered expression of
MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis.
Arthritis Rheum. 58, 1001–1009.
Steinman, L. (2010). Mixed results with modulation of TH-17 cells in human
autoimmune diseases. Nat. Immunol. 11, 41–44.
Taganov, K.D., Boldin, M.P., Chang, K.J., and Baltimore, D. (2006). NF-kap-
paB-dependent induction of microRNA miR-146, an inhibitor targeted to
signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA
103, 12481–12486.
Thai, T.H., Calado, D.P., Casola, S., Ansel, K.M., Xiao, C., Xue, Y., Murphy, A.,
Frendewey, D., Valenzuela, D., Kutok, J.L., et al. (2007). Regulation of the
germinal center response by microRNA-155. Science 316, 604–608.
Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stockinger, B.
(2006). TGFbeta in the context of an inflammatory cytokine milieu supports
de novo differentiation of IL-17-producing T cells. Immunity 24, 179–189.
Vigorito, E., Perks, K.L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas,
S., Das, P.P., Miska, E.A., Rodriguez, A., Bradley, A., et al. (2007). microRNA-
155 regulates the generation of immunoglobulin class-switched plasma cells.
Immunity 27, 847–859.
Xiao, C., and Rajewsky, K. (2009). MicroRNA control in the immune system:
Basic principles. Cell 136, 26–36.
Xiao, C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B., Wang, J.,
Henderson, J.M., Kutok, J.L., and Rajewsky, K. (2008). Lymphoproliferative
disease and autoimmunity in mice with increased miR-17-92 expression in
lymphocytes. Nat. Immunol. 9, 405–414.
Zhou, X., Jeker, L.T., Fife, B.T., Zhu, S., Anderson, M.S., McManus, M.T., and
Bluestone, J.A. (2008). Selective miRNA disruption in T reg cells leads to
uncontrolled autoimmunity. J. Exp. Med. 205, 1983–1991.Immunity 33, 607–619, October 29, 2010 ª2010 Elsevier Inc. 619
